Find us on:


Research Type
Reported as
Publication Type
Sort By
Total: 128
The effect of naltrexone as a carboplatin chemotherapy-associated drug on the immune response, quality of life and survival of dogs with mammary carcinoma
Research Type Animal Reported as Clinical Trial Date October 04, 2018 Authors Machado MC, da Costa-Neto JM, Portela RD, D'Assis MJMH, Martins-Filho OA, Barrouin-Melo SM, Borges NF, Silva FL, Estrela-Lima A. Institution Federal University of Bahi (Brazil), Federal University of Recôncavo da Bahia (Brazil), René Rachou Research Center, Estadual University of Santa Cruz (Brazil) Disease Cancer (general)
The objective of this study was to evaluate the effect of low-dose naltrexone (LDN) as a carboplatin chemotherapy-associated drug in female dogs with mammary carcinoma in benign mixed tumors (MC-BMT) after mastectomy and to assess its association with quality of life and survival rates. Sixty female dogs were included in this study, all of which had histopathological diagnosis of MC-BMT and were divided into three groups: G1 (control), consisting of animals submitted only to mastectomy with or w...
Successful treatment of dermatomyositis with low-dose naltrexone
Research Type Human Reported as Case Report/Series/Restrospective Study Date September 24, 2018 Authors Thanh Tran, Alessandra Chen, Scott Worswick Institution UCLA Disease Dermatomyositis
Low-dose naltrexone has been shown to treat autoimmune conditions, such as multiple sclerosis, fibromyalgia, and Crohn's disease. We present two cases in which low-dose naltrexone proved an effective therapy for dermatomyositis (DM), an idiopathic inflammatory myopathy. A search of PubMed for “low dose naltrexone” and “dermatomyositis” did not reveal any reported cases of the use of low-dose naltrexone in DM. We suspect that low-dose naltrexone produces an antiinflammatory effect via inh...
Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization
Research Type Human Reported as Review Date September 21, 2018 Authors Karlo Toljan, Bruce Vrooman Institution University of Zagreb; Dartmouth-Hitchcock Medical Center; Geisel School of Medicine at Dartmouth
Naltrexone and naloxone are classical opioid antagonists. In substantially lower than standard doses, they exert different pharmacodynamics. Low-dose naltrexone (LDN), considered in a daily dose of 1 to 5 mg, has been shown to reduce glial inflammatory response by modulating Toll-like receptor 4 signaling in addition to systemically upregulating endogenous opioid signaling by transient opioid-receptor blockade. Clinical reports of LDN have demonstrated possible benefits in diseases such as fibro...
Treatment of psoriasis vulgaris using low-dose naltrexone
Research Type Human Reported as Case Report/Series/Restrospective Study Date September 18, 2018 Authors Alanna C. Bridgman and Mark G. Kirchhof Institution Queen's University, University of Ottawa, The Ottawa Hospital Disease Psoriasis
A 60-year-old white woman presented with a history of moderate, generalized plaque psoriasis covering 10% of her body surface area (BSA). The patient began low-dose naltrexone, 4.5 mg daily. The patient's psoriatic lesions were significantly improved at 3 months, and the affected BSA had decreased from 10% to 1% after 6 months of treatment. The calculated PASI (psoriasis area severity index) score decreased from 7.2 to 0.9 after 6 months of treatment. Symptoms of pruritus also improved with nal...
Generalized familial benign chronic pemphigus (Hailey-Hailey disease) treated successfully with low-dose naltrexone
Research Type Human Reported as Case Report/Series/Restrospective Study Date August 01, 2018 Authors Natalie Kollman and Jonathan Blass Institution Case Western Reserve University School of Medicine Disease Hailey-Hailey
Hailey-Hailey disease, otherwise known as familial benign chronic pemphigus, is a genetic intraepidermal blistering disorder. In nongeneralized HHD, there have been a few published case reports of HHD treated successfully with low-dose naltrexone (LDN). The exact mechanism by which naltrexone works for HHD is unclear. The phenotypic expression of HHD can be quite variable. Although at times minimal, in rare cases, this disorder cannot only become generalized but result in systemic sequelae due...
Compounded Low-dose Naltrexone for the Treatment of Guttate Psoriasis: A Case Report
Research Type Human Reported as Case Report/Series/Restrospective Study Date July 15, 2018 Authors George Muller, Robert Grieshaber, Floyd Talley, Mike Riepl, Don Fellows Institution Compounding Business Services; Grieshaber Dermatology; Floyd's Family Pharmacy; Gateway Pharmacy Disease Psoriasis
The ancient autoimmune skin condition psoriasis is still ubiquitous worldwide, produces the same, often-intolerable effects noted in its earliest recorded descriptions, and remains without cure. Management options designed to resolve the itchy, scaly, weeping, erythematous, and often widespread lesions of that disorder are now available, but they vary in efficacy, most are associated with the development of severe adverse effects, and many are prohibitively expensive. In this article, we describ...
Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion
Research Type Human Reported as Case Report/Series/Restrospective Study Date July 05, 2018 Authors J.A. Miskoff, M. Chaudhri Institution Jersey Shore University Medical Center Disease Cancer (general), Lung Cancer
Low dose naltrexone (LDN) has been promising as a complementary medication for patients with a broad range of medical disorders. Although not a proven cure, evidence from clinical trials supports LDN as being a valuable adjunct for disorders in which the immune system plays a centralized role. Additionally, clinical trials have proposed a unique mechanism(s) allowing LDN to affect tumors including non-small cell lung cancer (NSCLC) at the cellular level by augmenting the immune system. We presen...
Double-blinded placebo-controlled cross-over pilot trial of naltrexone to treat Gulf War Illness
Research Type Human Reported as Clinical Trial Date June 09, 2018 Authors K.L. Brewer, A. Mainhart, W.J. Meggs Institution East Carolina University Disease Gulf War Illness
BACKGROUND: 30% of Gulf War veterans developed Gulf War Illness (GWI) with chronic fatigue, pain, and neuropsychological disabilities. PURPOSE: To assess the efficacy of low-dose naltrexone to treat GWI. Methods: A double-blinded, placebo-controlled crossover trial of naltrexone 4.5 mg/day was conducted. The Clinical global impression scale (CGIS), visual analogue scales (VAS), SF-36 Health Survey, and the Connors Continuous Performance Test assessed treatment response. ...
Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy
Research Type Human Reported as Review Date June 06, 2018 Authors Z. Li, Y. You, N. Griffin, J. Feng, F. Shan Institution Shengjing Hospital of China Medical University, Immune Therapeutics, Inc, China Medical University Disease AutoImmune (general), Cancer (general), Crohn's Disease, MS (Multiple Sclerosis)
Naltrexone, a non-selective antagonist of opioid receptors, is mainly used as rehabilitation therapy for discharged opiate addicts to eliminate addiction in order to maintain a normal life and prevent or reduce relapse. In recent years, there have been some novel and significant findings on the off-label usage of naltrexone. Within a specific dosage window, LDN can act as an immunomodulator in multiple autoimmune diseases and malignant tumors as well as alleviate the symptoms of some mental diso...
The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia
Research Type Lab (in-vitro) Date June 01, 2018 Authors Brianna Cote, Bethany Ross, Jeff Fortner, Deepa Rao Institution Oregon State University College of Pharmacy, Pacific University School of Pharmacy Disease Fibromyalgia
Fibromyalgia is a syndrome associated with chronic, widespread musculoskeletal pain, fatigue, depression, and cognitive dysfunction. With few U.S. Food and Drug Administration-approved treatment options, there is evidence that low-dose naltrexone, an opioid antagonist approved for opioid and alcohol dependence at high doses, may have efficacy in the treatment of fibromyalgia and chronic pain. At the doses required for fibromyalgia treatment, naltrexone needs to be compounded, and no data curre...